P. Sliwinski

TL;DR: In patients with RHTN, OSA and MS were the most frequent conditions, frequently overlapping with each other and also with PA, and in the vast majority of patients with truly R HTN, at least one of three co-morbidities—OSA, MS and PA is present.

TL;DR: In a randomized controlled trial, RDN lowered both office and ambulatory BP in patients with resistant hypertension and OSA and was accompanied by improvement of the clinical severity of OSA.

TL;DR: Both metabolic abnormalities and target organ damage are more pronounced in patients with RHTN, PA and OSA, and the presence of PA was associated with higher left ventricular mass and higher frequency ofleft ventricular hypertrophy.

TL;DR: Preliminary results of this on-going prospective OSA-PA study suggest that the prevalence of PA in hypertensive patients with moderate-to-severe OSA is 16%, and there were no differences in age, gender, blood pressure levels, frequency of MS and its components, Frequency of resistant hypertension, CVD and OSA symptoms between patients with PA and without PA.

TL;DR: In the studied group of patients with true resistant hypertension secondary causes were frequent, with moderate-severe OSA occurring in more than half patients, it may be postulated that in patients withtrue refractory hypertension secondary hypertension should be obligatory screened.